Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laurus LabsBOM:540222 -0.29%66 PS Ratio is 13.46 as of Aug. 04, 2026, which is 222% above its 10-year median of 4.18. GuruFocus rates BOM:540222 with a GF Score™ of 66/100 and a GF Value™ of ₹822.64 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 954 Drug Manufacturers companies, Laurus Labs ranks worse than 91.09% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Laurus Labs's share price is ₹1811.00.
Laurus Labs's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹134.51. Hence, Laurus Labs's PS Ratio for today is 13.46.
Warning Sign:
Laurus Labs Ltd stock PS Ratio (=13.24) is close to 10-year high of 13.24.
The historical rank and industry rank for Laurus Labs's PS Ratio or its related term are showing as below:
BOM:540222'
s PS Ratio Range Over the Past 10 Years
Min: 1.32 Med: 4.18 Max: 13.5
Current: 13.5
During the past 13 years, Laurus Labs's highest PS Ratio was 13.50. The lowest was 1.32. And the median was 4.18.
BOM:540222's PS Ratio is ranked worse than 91.09% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs BOM:540222: 13.50
During the past 12 months, the average Revenue per Share Growth Rate of Laurus Labs was 22.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 14.80% per year.
During the past 13 years, Laurus Labs's highest 3-Year average Revenue per Share Growth Rate was 32.70% per year. The lowest was 1.80% per year. And the median was 8.15% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Laurus Labs PS Ratio Related Terms
Laurus Labs PS Ratio Historical Data
* Premium members only.
The historical data trend for Laurus Labs's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laurus Labs PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's PS Ratio distribution charts can be found below:
* The bar in red indicates where Laurus Labs's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Laurus Labs's Share Price of today is ₹1811.00. Laurus Labs's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹134.51.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Laurus Labs (BOM:540222) has a PS Ratio of 13.46 as of Aug. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Laurus Labs and its competitors. This is 222% above median its historical median of 4.18. Over the past decade, Laurus Labs' PS Ratio has ranged from 1.32 to 13.50. According to the industry distribution chart, Laurus Labs ranks #869 out of 954 companies in the Drug Manufacturers industry, placing it in the top 91.1%.
Is Laurus Labs' PS Ratio too high?
Laurus Labs' current PS Ratio of 13.46 is 222% above median its 10-year median of 4.18. Over the past 10 years, this metric has ranged from a low of 1.32 to a high of 13.50. The Drug Manufacturers industry median PS Ratio is 2.32. Laurus Labs' value of 13.46 is 480.2% above this industry median. Based on the distribution chart, Laurus Labs ranks #869 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Laurus Labs ranks #869 out of 954 companies for PS Ratio. This places Laurus Labs in the lower half of its industry. The industry median PS Ratio is 2.32. Laurus Labs' value of 13.46 is 480.2% above this benchmark. Historically, Laurus Labs' own PS Ratio has ranged from 1.32 to 13.50 over the past decade. While the company's 10-year median is 4.18 vs. the industry median of 2.32, Laurus Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laurus Labs's current PS Ratio of 13.46 is 480.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Laurus Labs and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laurus Labs's current PS Ratio is 13.46, which is 222% above median its own 10-year median of 4.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹822.64, compared to a current price of ₹1,811.00 — trading 120.1% above its estimated fair value. The current PS Ratio is 13.46, which is 222% above median its 10-year median of 4.18 and 480.2% above the Drug Manufacturers industry median of 2.32. Laurus Labs' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current PS Ratio is 13.46 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laurus Labs (BOM:540222) Overvalued in 2026?
Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued.
The current stock price of ₹1,811.00 is trading 120.1% above its estimated GF Value™ of ₹822.64.
GuruFocus considers Laurus Labs to be Significantly Overvalued.
Key valuation signals for BOM:540222:
PS Ratio: 13.46 (222% above median its 10-year median of 4.18)
GF Value™: ₹822.64 vs. price of ₹1,811.00 (120.1% above fair value)
Industry Position: 480.2% above the Drug Manufacturers median (#869 of 954)
No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score
Get the complete analysis for BOM:540222
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540222 has been successfully added to your 
